Categories: Finance

Rupak De’s Top Picks: Should You Buy or Sell These 3 Stocks NOW?

F&O Strategy: Should You Bet on Manappuram, Biocon, or Karur Vysya Right Now?

Alright, let’s talk shop. Rupak De—yeah, that guy from LKP Securities who’s always on TV—just dropped his latest F&O picks. Manappuram Finance, Biocon, and Karur Vysya Bank. Now, I know what you’re thinking: “Another analyst, another set of predictions.” But here’s the thing—De’s track record isn’t half bad. And with GIFT Nifty doing its usual rollercoaster thing (up 100 points one day, down the next), his timing might actually matter this time. So, let’s peel this onion.

1. What’s Cooking in the F&O Market?

Market Mood: Hopeful or Just Nervous?

So the GIFT Nifty jumped 100 points. Big deal, right? But here’s the kicker—weekly expiry’s around the corner, and you know how that goes. Volatility spikes, stop losses get triggered left and right. It’s like trying to drink chai on a local train—messy, but kinda thrilling if you don’t spill.

How Rupak De Reads the Chaos

“Charts don’t lie, but they don’t spell everything out either,” he told me last week. And he’s got a point. The guy lives for RSI crossovers and moving averages—basic tools, sure, but when the market’s this jumpy? Sometimes simple works best.

2. Breaking Down De’s Top Picks

Manappuram Finance: Golden Opportunity or Fool’s Gold?

De’s calling a bullish flag pattern here. Fancy term, but basically he thinks if it cracks ₹185, we could see a nice 10% run. Stop loss at ₹172, just in case. But—and this is a big but—NBFCs have been sketchy lately with all the debt worries. So maybe don’t go all in.

Biocon: The Waiting Game

This one’s been stuck around ₹270 like my cousin’s Maruti 800 on a Mumbai monsoon day. De says it’s “compressing before expansion”—which sounds smart, but really means it could either pop to ₹300 or just keep sitting there. Pharma stocks, man. Always one FDA letter away from drama.

Karur Vysya Bank: Banking on a Breakout

See this ₹140-160 range it’s been stuck in? De’s eyeing something called a descending triangle (sounds scary, but just means it’s probably gonna move soon). His call: buy above ₹158, aim for ₹175. But banks these days? More unpredictable than Bangalore traffic.

3. The Good, The Bad, and The “Maybe”

Sector Stuff You Should Know

Manappuram’s got rural demand going for it. Biocon’s all about those biosimilars (think generic biotech drugs). Karur Vysya? Pure play on whether people keep borrowing money. Problem is, when sectors rotate, someone always gets left holding the bag.

Liquidity Check

All three trade decent volumes, but Biocon’s spreads can be annoying—like trying to bargain at Crawford Market. And with earnings season coming? Buckle up.

4. Should You Ride With Rupak De?

Why You Might Want To

Guy called PSU banks right last year—20% gains for those who listened. When his charts and sector trends align, like with Manappuram now? Worth a look.

Why You Might Want To Think Twice

False breakouts happen more than you’d think. And let’s be real—no chart predicts stuff like random geopolitical messes. Maybe pair his views with some old-school fundamental checks.

5. Other Smart People Disagree (Because Of Course They Do)

Different Strokes

Rupesh Tomar over at Linknovate’s all about HDFC Bank instead of Karur Vysya—calls regional banks “overheated.” Biocon? Analysts can’t decide if it’s a steal or a regulatory time bomb.

Bottom Line

Here’s how I see it: Manappuram’s chart looks prettiest, Biocon needs something to wake it up, and Karur Vysya’s all about perfect timing. My two paisa? Maybe take small positions, keep those stop losses tight, and don’t bet the farm. Market’s jumpy enough without us adding fuel.